Skip Navigation


European Heart Journal Advance Access originally published online on November 10, 2006
European Heart Journal 2006 27(24):2916-2918; doi:10.1093/eurheartj/ehl376
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/24/2916    most recent
ehl376v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in EHJ
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Shimada, K.
Right arrow Articles by Daida, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimada, K.
Right arrow Articles by Daida, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?

Kazunori Shimada1,*, Jin Kyun Park2 and Hiroyuki Daida1

1 Department of Cardiovascular Medicine, Juntendo University School of Medicine, 2-1-1 Hongo Bunkyo-ku, Tokyo 113-8421, Japan
2 Department of Medicine, University of Florida College of Medicine, USA

* Corresponding author. Tel: +81 3 5802 1056; fax: +81 3 5689 0627. E-mail address: shimakaz@med.juntendo.ac.jp

This editorial refers to ‘Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome’{dagger} by A. Link et al., on page 2945

The first 10% of the full text of this article appears below.

Immunity is derived from the Latin word immunitas, which means protection from civic duties and prosecution for a Roman Senator. Today, the principal function of the immune system is the protection of individuals against infectious agents and unsafe foreign (or endogenous) substances. This defence system comprises the early responses, namely innate immunity, and late reactions, called adaptive immunity. Innate immunity is the first line of defence that can be rapidly mobilized to detect pathogen-associated molecular patterns (PAMPs) using PAMP receptors (e.g. scavenger receptors and Toll-like receptors) on the surface of antigen-presenting cells (APCs), such as macrophages and dendritic cells. Adaptive immunity is the antigen-specific immune responses mainly consisting of lymphocytes. There are two types of adaptive immune responses: cell-mediated immunity and humoral immunity (Figure 1). In 1986, Mosmann et al.1 demonstrated for the first time that two types of CD4+ T helper . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in EHJ:

Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome
Andreas Link, Tarek Ayadhi, Michael Böhm, and Georg Nickenig
EHJ 2006 27: 2945-2955. [Abstract] [FREE Full Text]